AgomAb Therapeutics NV (NASDAQ:AGMB) secured a U.S. patent for its investigational drug AGMB-447, an ALK5 inhibitor for idiopathic pulmonary fibrosis, providing protection through at least 2041. This news follows optimistic analyst coverage from Leerink and JPMorgan, who issued Outperform and Overweight ratings, respectively, citing upcoming data readouts and promising pipeline developments. The company is poised for a significant year in 2026 with potential upsides in its treatments for fibrotic and inflammatory bowel diseases.
Leerink has initiated coverage on AgomAb Therapeutics (NASDAQ: AGMB) with an "Outperform" rating and a price target of $36. This announcement comes alongside similar "Overweight" initiations from JPMorgan and Morgan Stanley on the same day, indicating positive analyst sentiment for the biotechnology company. AgomAb had recently completed a $200 million IPO in early February.
Stifel analyst James Condulis initiated coverage on Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) with a Buy rating and a $21 price target. This article also highlights three other significant analyst initiations for Tuesday, including Goldman Sachs on Once Upon A Farm PBC (NYSE: OFRM), Morgan Stanley on Agomab Therapeutics NV (NASDAQ: AGMB), and Stifel on SpyGlass Pharma, Inc. (NASDAQ: SGP), all with bullish ratings and specific price targets.
